Universal mass vaccination against rotavirus gastroenteritis: Impact on hospitalization rates in Austrian children

Pediatric Infectious Disease Journal

Volumn 29, Issue 4, 2010, Pages 319-323

  Paulke Korinek, Maria ^a   Rendi Wagner, Pamela ^a,b   Kundi, Michael ^c   Kronik, Renate ^a   Kollaritsch, Herwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immunization program; Rotavirus gastroenteritis; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; APNEA; ARTICLE; AUSTRIA; CHILD; CONTROLLED STUDY; DIARRHEA; FEMALE; HOSPITAL CHARGE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPERVENTILATION; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; PEDIATRIC WARD; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RESTLESSNESS; ROTAVIRUS GASTROENTERITIS; SLOPPY INFANT; VIRAL GASTROENTERITIS; VOMITING;

EID: 77950278583     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c18434     Document Type: Article

References (28)

1. Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: current prospects and future challenges. Lancet. 2006;368:323-332.
2. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J. 2006;25(suppl 1):S7-S11.
3. Cortese M, Parashar U. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2009;58(RR-2):1-25.
4. Frühwirth M, Heininger U, Ehlken B, et al. International variation in disease burden of rotavirus gastroenteritis in children with community-and nosocomially acquired infection. Pediatr Infect Dis J. 2001;20:784-791.
5. Rendi-Wagner P, Kundi M, Mikolasek A, et al. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr. 2006;118:280-285.
6. Frühwirth M, Berger K, Ehlken B, et al. Economic impact of community-and nosocomially acquired rotavirus gastroenteritis in Austria. Pediatr Infect Dis J. 2001;20:184-188.
7. Obester Sanitätsrat. Ö sterreichischer Impfplan 2006; October 18, 2005. Available at: http://www.schule.at/dl/s0148eb4.pdf. Accessed December 16, 2008.
8. Wilhelmi I, Colomina J, Martín-Rodrigo D, et al. New immunochromato-graphic method for rapid detection of rotaviruses in stool samples compared with standard enzyme immunoassay and latex agglutination techniques. Eur J Clin Microbiol Infect Dis. 2001;20:741-743.
9. Crehalet H, Vandenesch F, Freydiere AM. Rapid detection of rotavirus in children: comparison of Vikia Rota-Adeno and Diarlex MB, two immuno-chromatographic tests. 16th ECCMID Nice-Avril 2006, P634. Available at: http://www.biomerieux-diagnostics.com/uploadVIKIA-Rota-Adeno-PosterAMFNice6- 2006.pdf Accessed September 14, 2009.
10. Eing BR, May G, Baumeister HG, et al. Evaluation of two enzyme immunoassays for detection of human rotaviruses in fecal specimens. J Clin Microbiol. 2001;39:4532-4534.
11. Kux K. Handbuchfur die Sanitätsberufe Osterreichs. 2nd Version. Vienna, Austria: Dieter Goschl Ges.mbH; 2006.
12. Statistik Austria. Demographisches Jahrbuch 2007. Wien, Austria: Statistik Austria, Bundesanstalt Statistik Osterreich; November 2008. Available at: http://www.statistik.at/web-de/dynamic/statistiken/bevoelkerung/ bevoelkerungsstruktur/bevoelkerung-nach-alter-geschlecht/publdetail?id= 684&listid=684&detail=490. Accessed April 7, 2009.
13. Heinz FX, Holzmann H, Essl A, et al. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 2007;25:7559-7567.
14. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33.
15. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11-22.
16. De Vos B, Han HH, Bouckenooghe A, et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes. Integrated analysis of randomized controlled trials. Pediatr Infect Dis J. 2009;28:261-266.
17. De Oliveira L, Danovaro-Holliday M, Matus C, et al. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines. 2008;7:345-353.
18. Australian Government, Department of Health and Ageing. National Immunisation Program (NIP) Schedule. April 8, 2008. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips. Accessed March 28, 2009.
19. Parashar UD, Alexander JP, Glass R Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR12):1-13.
20. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMWR. 2008;57:697-700.
21. EUVAC.NET. A Surveillance Community Network for Vaccine Preventable Infectious Diseases. 2008. Available at: http://www.euvac.net/graphics/euvac/ vaccination/vaccination.html. Accessed December 12, 2008.
22. Gossens LM, Standaert B, Hartwig N, et al. Conclusion on the cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Vaccine. 2009;27:2531-2532.
23. Panatto D, Amicizia D, Ansaldi F, et al. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine. 2009;27:3450-3453.
24. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007; 370:1757-1763.
25. Ciarlet M, He S, Lai S, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J. 2009;28:177-181.
26. Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1181-1189.
27. Paul Ehrlich Institut. Informationen des Paul-Ehrlich-Instituts zu Mel-dungen von Kawasaki-Syndrom in zeitlichem Zusammenhang mit der Rotavirus-Impfung 2009. February 2, 2009. Available at: http://www. pei.de/cln-115/nn-158134/DE/infos/fachkreise/am-infos-ablage/sik/ 2009-02-01-kawasaki-syndrom.html. Accessed March 13, 2009.
28. Geier DA, King PG, Sykes LK, et al. RotaTeq vaccine adverse events and policy considerations. Med Sci Monit. 2008;14:PH9-PH16.